Activity-based proteome profiling of potential cellular targets of Orlistat--an FDA-approved drug with anti-tumor activities.
about
Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparumA quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasisChemical proteomics approaches for identifying the cellular targets of natural productsMmPPOX inhibits Mycobacterium tuberculosis lipolytic enzymes belonging to the hormone-sensitive lipase family and alters mycobacterial growthCharacterization of an acid inducible lipase Rv3203 from Mycobacterium tuberculosis H37RvA Clickable Analogue of Ketamine Retains NMDA Receptor Activity, Psychoactivity, and Accumulates in Neurons.Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition ReactionsIn situ imaging and proteome profiling indicate andrographolide is a highly promiscuous compound.Acute lipotoxicity regulates severity of biliary acute pancreatitis without affecting its initiationTetrazine ligation for chemical proteomics.A concise, phosphate-mediated approach to the total synthesis of (-)-tetrahydrolipstatin.Applying small molecule microarrays and resulting affinity probe cocktails for proteome profiling of mammalian cell lysates.A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent.Chemical proteomics and its impact on the drug discovery process.Chemistry-based functional proteomics for drug target deconvolution.Target analysis of α-alkylidene-γ-butyrolactones in uropathogenic E. coli.Target identification for small bioactive molecules: finding the needle in the haystack.Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling.Multiplex imaging and cellular target identification of kinase inhibitors via an affinity-based proteome profiling approach.Cell permeable affinity- and activity-based probes.Mapping proteome-wide interactions of reactive chemicals using chemoproteomic platforms.A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.Synthesis and kinetic evaluation of cyclophostin and cyclipostins phosphonate analogs as selective and potent inhibitors of microbial lipases.Problems and Solutions in Click Chemistry Applied to Drug Probes.Bioorthogonal approach to identify unsuspected drug targets in live cells.Reversible lipid accumulation and associated division arrest of Mycobacterium avium in lipoprotein-induced foamy macrophages may resemble key events during latency and reactivation of tuberculosisTargeting lipid esterases in mycobacteria grown under different physiological conditions using activity-based profiling with tetrahydrolipstatin (THL).Remodeling natural products: chemistry and serine hydrolase activity of a rocaglate-derived β-lactone.Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs.From noncovalent to covalent bonds: a paradigm shift in target protein identification.Chemical proteomic strategies for the discovery and development of anticancer drugs.Activity-based protein profiling: recent advances in probe development and applications.Making a Long Journey Short: Alkyne Functionalization of Natural Product Scaffolds.Target identification of natural products and bioactive compounds using affinity-based probes.Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons.Activity-based profiling of the proteasome pathway during hepatitis C virus infection.Characterization of LipN (Rv2970c) of Mycobacterium Tuberculosis H37Rv and its Probable Role in Xenobiotic Degradation.Targeted Covalent Inhibitors for Drug Design.Live cell off-target identification of lapatinib using ligand-directed tosyl chemistry.
P2860
Q22061870-80D95A9F-123C-46C3-B69B-CB67D58E56A4Q23005474-699949F5-5E7D-44EC-9993-229E86EF7D34Q28072634-6E1CC061-3500-4E50-BFDF-B919170BF891Q28484106-A58E4A98-770A-4C8C-8106-D691CEF540EBQ28486836-A15ED423-40FC-4C61-8B01-BD3F45D2C150Q28817259-9B7F02EB-FA67-4377-8254-48F9D807051EQ29248430-4BDDE4AD-DC2D-4201-A02E-C87332213C8EQ30655482-B278A17E-2679-4D8B-92B4-6A28A2E5FFB7Q33708690-02610AC4-6B39-43BE-BA72-A96CB6CA5C82Q33837728-839DE66D-57EB-4E08-80DB-23D8E25D37D4Q33922563-A6635B34-825D-4996-83C4-4B6ADE6A40F0Q34013178-772635D6-2C1B-4FD7-B493-BA090A6F0A84Q34067085-D53C10E5-4F60-4DFC-B740-EB65D124B59AQ34279501-922E9349-40B9-4B10-BB6A-194B401841CBQ34342900-AA00BB83-9EFD-4CB9-A0C5-B9F9F46DE1C9Q34342905-F29EF17A-47CF-43B5-9485-09CBF6854C38Q34418282-03C715DD-AE79-4B8D-93F0-2B5A9B7FDF91Q34589404-92A33CCE-D2AC-4E03-AE08-7D1D7089B8DEQ34765081-6670A3F4-EAFC-41DC-9B26-D906DDF8C4CBQ34908239-2C0A62F0-245E-4A69-B442-5306E5F60EE1Q35825193-74FF75EB-3797-4B89-9D23-EB23684C0ED1Q35863703-2206632B-8111-461E-B27E-83052D6B2F7AQ36290627-FE689DD2-8A55-4FF0-8D55-079543570817Q36455458-1CC243CA-ACC5-413F-8E50-4580EC3729F4Q37366792-6C7A1CE7-B56D-4240-9B71-9988BEECB734Q37376761-169A8275-6509-41E6-B746-2DF839D7BD0BQ37546501-7F247710-8972-474C-B63C-456A03889F61Q37563877-A3C54921-7EBF-4B1A-8D44-C9E35EE619DCQ37689578-BD022CA2-0858-4584-8D68-4EC2DEA5715DQ38019608-A9CAC751-69E0-4438-BA7A-4262F15B71B8Q38077052-21C05408-F220-4D69-9DC9-C758A850C1ECQ38170023-D3C0A658-B255-4BD7-B803-F158EC62B39CQ38344349-3E944F0E-3CE8-477C-BFAC-AB621202495DQ38560741-5CD1183B-015A-4B13-8A2C-CC7B3FA76DEAQ38637266-42ED8780-4D37-4A63-825B-3FE257564326Q38713130-FB1A10F8-F23D-494A-8F6E-93405CB376A0Q38840313-771340CB-90CA-460D-872B-05AC6B335174Q38849174-FB28E9A5-B02E-495A-A889-9B509AA930B6Q38931379-88D09B7A-60E5-4C00-8B61-9EA6856A6B33Q38951305-DF2FB59C-29BC-4791-AF38-43D642AF8F13
P2860
Activity-based proteome profiling of potential cellular targets of Orlistat--an FDA-approved drug with anti-tumor activities.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Activity-based proteome profil ...... ug with anti-tumor activities.
@ast
Activity-based proteome profil ...... ug with anti-tumor activities.
@en
Activity-based proteome profil ...... ug with anti-tumor activities.
@nl
type
label
Activity-based proteome profil ...... ug with anti-tumor activities.
@ast
Activity-based proteome profil ...... ug with anti-tumor activities.
@en
Activity-based proteome profil ...... ug with anti-tumor activities.
@nl
prefLabel
Activity-based proteome profil ...... ug with anti-tumor activities.
@ast
Activity-based proteome profil ...... ug with anti-tumor activities.
@en
Activity-based proteome profil ...... ug with anti-tumor activities.
@nl
P2093
P356
P1476
Activity-based proteome profil ...... ug with anti-tumor activities.
@en
P2093
Markus R Wenk
Mun Hong Ngai
Shao Q Yao
P304
P356
10.1021/JA907716F
P407
P577
2010-01-01T00:00:00Z